Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment

Inclusion criteria

• Aged 35-80 years;
• Stroke duration within 2 weeks to 6 months post-onset;
• Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score < 26;
• Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.);
• No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study;
• Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.

Exclusion criteria

• Unstable vital signs or life-threatening comorbidities;
• Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.);
• History of epilepsy or epileptic seizures;
• Pregnant or lactating women;
• Concurrent use of other medications affecting cognitive function;
• Allergy to the study intervention device or history of serious adverse reactions;
• Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.);
• Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.